我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
隶属于 Daiichi Sankyo Co., Ltd.
相关临床试验
65
6 进行中
药物批准
93
批准总数
监管机构
1
监管机构数
成立时间
1967
进行中（未招募）
6
9.2%
已完成
45
69.2%
招募中
终止
3
4.6%
撤回
5
7.7%
FDA
Food and Drug Administration
- American Regent, Inc. has issued a voluntary nationwide recall of one lot of Papaverine Hydrochloride Injection, USP, 60 mg/2 mL due to the presence of glass and/or paraformaldehyde particulate matter. - The contaminated particulate matter could travel through blood vessels and block vessels in the heart, lungs, or brain, potentially causing stroke or death. - Lot #25202 was distributed nationwide beginning September 30, 2025, with an expiration date of November 30, 2026, and no adverse events have been reported to date. - Healthcare facilities and consumers are instructed to stop using the recalled product immediately and return it to the place of purchase or discard it.
